STAT Proteins: From Normal Control of Cellular Events to Tumorigenesis

Journal of Cellular Physiology

Volumn 197, Issue 2, 2003, Pages 157-168

  Calò, Valentina ^a   Migliavacca, Manuela ^a   Bazan, Viviana ^a   Macaluso, Marcella ^a,b   Buscemi, Maria ^a   Gebbia, Nicola ^a   Russo, Antonio ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b TEMPLE UNIVERSITY   (United States)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CETUXIMAB; CYCLIN D1; CYTOKINE; ERYTHROPOIETIN; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 ANTAGONIST; JANUS KINASE; MONOCLONAL ANTIBODY; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PD 0169414; PROLACTIN; PROTEIN BCL XL; PROTEIN SERINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SANT 7; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; STAT1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CLINICAL TRIAL; DNA BINDING; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HEAD AND NECK CANCER; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; LEUKEMIA; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; ANIMAL; EUKARYOTIC CELL; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; EUKARYOTIC CELLS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 0242285719     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.10364     Document Type: Review

References (113)

1. Akira S. 2000. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 19(21):2607-2611.
2. Aoki N, Matsuda TA. 2002. A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway; dephosphorilation and deactivation of signal trasducer and activator of transcription 5a and 5b by TC-PTP in nucleus. Mol Endocrinol 16:58-69.
3. Baselga J. 2000a. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 18(Suppl 21):54S-59S.
4. Baselga J. 2000b. Current and planned clinical trials with trastuzumab (Herceptin). Semin Oncol 27(5 Suppl 9):27-32.
5. Becker S, Groner B, Muller CW. 1998. Three-dimensional structure of the STAT3b homodimer bound to DNA. Nature (Lond) 394:145-151.
6. Bowman T, Garcia R, Turkson J, Jove R. 2000. STATs in oncogenesis. Oncogene 19(21):2474-2488.
7. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R. 2001. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 98(13):7319-7324.
8. Briscole J, Kohlhuber F, Muller M. 1996. JAKs and STATs branch out. Trends Cell Biol 6:336-340.
9. Bromberg JF. 2002. Stat proteins and oncogenesis (review). J Clin Invest 109(9):1139-1142.
10. Bromberg J, Darnell JE, Jr. 2000. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19:2468-2473.
11. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE, Jr. 1998. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18(5):2553-2558.
12. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE, Jr. 1999. Stat3 as an oncogene. Cell 98(3): 295-303.
13. Buettner R, Mora LB, Jove R. 2002. Activated Stat signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945-954.
14. Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel MT, Bernard O, Ghysdael J. 2000. Tel-Jak2 transgenic mice develop T-cell leukemia. Blood 95:3891-3899.
15. Catlett-Falcone R, Dalton WS, Jove R. 1999. STAT proteins as novel targets for cancer therapy. Curr Opin Oncol 11:490-496.
16. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, Akira S, Clarke AR, Watson CJ. 1999. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13:2604-2616.
17. Chatterjee-Kishore M, Van De Akker F, Stark GR. 2000a. Association of STATs with relatives and friend. Trends Cell Biol 10(3): 106-111.
18. Chatterjee-Kishore M, Wright KL, Ting JP, Stark GR. 2000b. How Stat1 mediates constitutive gene expression: A complex of unphosphorylated Stat1 and IRF1 supports transcription of LMP2 gene. EMBO J 19(15):4111-4122.
19. Chen X, Vinkemeier U, Zhao Y, Jeruzalmu D, Darnell JE, Kuriyan J. 1998. Crystal structure of a tyrosine phosphorilated Stat-1 dimer bound to DNA. Cell 93:827-839.
20. Chen E, Gadina M, Chen M, O'Shea JJ. 1999. Advances in cytokine signaling: The role of Jaks and STATs (review). Transplant Proc 31:1482-1487.
21. WAF/CIP1mediated by STAT1. Science 272(5262):719-722.
22. Choudhury GG, Ghosh-Choudhury N, Abboud HE. 1998. Association and direct activation of signal transducer and activator of transcription1alpha by platelet-derived growth factor receptor. J Clin Invest 101(12):2751-2760.
23. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. 1997. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278:1803-1805.
24. Coffer PJ, Koenderman L, de Groot RP. 2000. The role of Stats in myeloid differentiation and leukemia. Oncogene 19:2511-2522.
25. Collum RG, Brutsaert S, Lee G, Schindler C. 2000. A Stat3-interacting protein (StIP1) regulates cytokine signal transduction. Proc Natl Acad Sci USA 97:10120-10125.
26. Dalton WS, Jove R. 1999. Drug resistance in multiple myeloma: Approaches to circumvention. Review. Semin Oncol 26(5 Suppl 13):23-27.
27. Danial NN, Pernis A, Rothman PB. 1995. Jak-STAT signaling induced by the v-abl oncogene. Science 269(5232):1875-1877.
28. Darnell JE, Jr. 1997. STATs and gene regulation. Science 277:1630-1635.
29. David M, Petricoin E III, Benjamin C, Pine R, Weber MJ, Larner AC. 1995. Requirement for MAPkinase (ERK2) activity in interferon alpha- and interferon beta stimulated gene expression through STAT proteins. Science 269:1721-1723.
30. de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L. 1999. Stat5 activation by Bcr-Abl contributes to transformation of K562 leukaemia cells. Blood 94:1108-1112.
31. de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L. 2000. Stat5-dependent cyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 3(5):299-305.
32. Decker T, Kovarik P. 1999. Transcription factor activity of Stat proteins: Structural requirements and regulation by phosphorilation and interacting proteins. Cell Mol Life Sci 55:1509-1522.
33. Decker T, Kovarik P. 2000. Serine phosphorylation of STATs. Oncogene 19:2628-2637.
34. Dell'Albani P, Santangelo R, Torrisi L, Nicoletti VG, Giuffrida Stella AM. 2003. Role of the JAK/STAT signal transduction pathway in the regulation of gene expression in CNS. Neurochem Res 28(1):53-64.
35. Dumon S, Santos SC, Debierre-Grockiego F, Gouilleux-Gruart V, Cocault L, Boucheron C, Mollat P, Gisselbrecht S, Gouilleux F. 1999. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Oncogene 18(29):4191-4199.
36. Durbin JE, Hackenmiller R, Simon MC, Levy DE. 1996. Targed distruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84:443-450.
37. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP, Jr. 2001. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107(3):351-362.
38. Fu XY, Zhang JJ. 1993. Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter. Cell 74(6):1135-45.
39. Fukada T, Ohtani T, Yoshida Y, Shirogane T, Nishida K, Nakajima K, Hibi M, Hirano T. 1998. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J 17:6670-6677.
40. Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP, Jove R. 1997. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 8(12):1267-1276.
41. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R. 2001. Constitutive activation of Stat3 by the Src and Jak tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499-2513.
42. Goh KC, Haque SJ, Williams BR. 1999. p38 MAPkinase is required for STAT1 serine phosphorylation and trascriptional activation induced by interferon. EMBO J 18:5601-5608.
43. Gooch J, Lee AV, Yee D. 1998. Interleukin-4 inhibits growth and induces apoptosis in human breast cancer cells. Cell Growth Differ 6:335-342.
44. Gooch J, Christy B, Yee D. 2002. STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia 4(4):324-331.
45. Grandis JR, Grenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ. 1998. Requirement of Stat3 but not Stat1 activation for epidermel growth factor receptor-mediated cell growth in vitro. J Clin Invest 102(7):1385-1392.
46. Horvath CM. 2000. STAT proteins and transcriptional responses to extracellular signals. TIBS 25:496-502.
47. Horvath CM, Stark GR, Kerr IM, Darnell JE, Jr. 1996. Interactions between STAT and non-STAT proteins in the interferon stimulated gene factor 3 transcription complex. Mol Cell Biol 19:5106-5112.
48. Hou J, Schindler U, Henzel WJ, Ho TC, Braseur M, McKnight SL. 1994. An interleukine-4-induced transcription factor: IL-4 Stat. Science 265:1701-1706.
49. Huang M, Page C, Reynold RK, Lin J. 2000. Constitutive activation of Stat3 oncogene product in human ovarian carcinoma cells. Gynec Oncol 79:67-73.
50. Hung W, Elliott B. 2001. Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells. J Biol Chem 276(15):12395-12403.
51. Ibarra-Sanchez MJ, Simoncic PD, Nestel FR, Duplay P, Lapp WS, Tremblay ML. 2000. The T-cell protein tyrosine phosphatase. Semin Immunol 12(4):379-386 (review).
52. Ihle JN. 2001. The STAT family in cytokine signaling. Curr Opin Cell Biol 13:211-217.
53. Imada K, Leonard WJ. 2000. The Jak-STAT pathway. Mol Immunol 37:1-11.
54. Imada K, Bloom ET, Nakajima H, Horvarth-Arcidiacono JA, Udy JB, Davey HW, Leonard WJ. 1998. Stat5b is essential for natural killer cell-mediated proliferation and cytotoxit acitivy. J Exp Med 188:2066-2074.
55. John S, VinKemeier U, Soldaini E, Darnell JE, Jr, Leonard WJ. 1999. The significance of tetrameization in promoter recruitment by STAT5. Mol Cell Biol 19:1910-1918.
56. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95:7556-7561.
57. Kile BT, Nicola NA, Alexander WS. 2001. Negative regulators of cytokine signaling. Int J Hematol 73:292-298.
58. Kisseleva T, Bhattacharya S, Schroeder-Braunstein J, Schindler CW. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285:1-24.
59. Krebs DL, Hilton DJ. 2001. SOCS proteins: Negative regulators of cytokine signaling. Stem Cells 19:378-387.
60. Kumar A, Commane M, Flickinger TW, Horwath CM, Stark GR. 1997. Detective TNF-alpha-induced apoptosis in Stat1-null cells due to low costitutive levels of caspases. Science 278:1630-1632.
61. Levy DE, Darnell JE, Jr. 2002. STATs: Transcriptional control and biological impact. Nat Rev 3:651-662.
62. Levy DE, Lee C. 2002. What does stat3 do? J Clin Invest 9:1143-1148.
63. Li X, Leung S, Burns C, Stark GR. 1998. Cooperative binding of Stat1-2 heterodimers and ISGF3 to tandem DNA elements. Biochem J 80:703-710.
64. Lin TS, Mahajan S, Frank DA. 2000. Stat signaling in the pathogenesis and treatment of leukemias. Oncogene 19:2496-2504.
65. Liu X, Robinson GW, Wagner K-U, Garrett L, Wynshaw-Boris A, Hennighausen L. 1997. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11:179-186.
66. Lord JD, McIntosh BC, Greenberg PD, Nelson BH. 2000. The IL-2 receptor promotes lymphocytes proliferation and induction of the c-myc, bcl-2 and bcl-x genes through the transactivation domain of Stat5. J Immunol 164:2533-2541.
67. Martino A, Holmes JH IV, Lord DJ, Moon JJ, Nelson BH. 2001. STAT5 and Sp1 regulate the transcription of the cyclin D2 gene in response to IL-2. J Immunol 166:1723-1729.
68. Matsumara I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, Downward J, Pestell RG, Kanakura Y. 1999. EMBO J 18:1367-1377.
69. McBride KM, Banninger G, McDonald C, Reich NC. 2002. Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-α. EMBO J 21:1754-1763.
70. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD. 1996. Target disruption of the Stat1 gene in mice reveals unexpected physiologic specificità in the JaK-STAT signaling pathway. Cell 84:431-442.
71. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM. 1996. Inhibition of acute lymphoblastic leukaemia by a Jak2 inhibitor. Nature 379:645-648.
72. Murakami Y, Nakano S, Niho Y, Hamasaki N, Izuhara K. 1998. Constitutive activation of Jak-2 and Tyk-2 in a v-Src-transformed human gallbladder adenocarcinoma cell line. J Cell Physiol 175(2): 220-228.
73. Ning ZQ, Li J, McGuinness M, Arceci RJ. 2001. STAT3 activation is required for Asp(816) mutant c-Kit inducedtumorigenicity. Oncogene 20(33):4528-4536.
74. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. 2002. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13):2000-2008.
75. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T. 1999. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 18(17):4754-4765.
76. Ouchi T, Lee SW, Ouchi M, Aaroson SA, Horvath CM. 2000. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-g target genes. Proc Natl Acad Sci USA 97(10):5208-5213.
77. Quelle FW, Thierfelder W, Witthuhn BA, Tang B, Cohen S, Ihle JN. 1995. Phosphorylation and activation of the DNA binding activity of purified Stat1 by the Janus protein-tyrosine kinases and the epidermal growth factor receptor. J Biol Chem 270(35):20775-20780.
78. Ramana CV, Grammatikakis N, Chernov M, Nguyn H, Goh KC, Williams BR, Stark GR. 2000. Regulation of c-myc expression by IFN-γ through Stat1-dependent and -independent pathways. EMBO J 19:263-272.
79. Sachdev S, Bruhn L, Pichler A, Melchior F, Crosschedl XX. 2001. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 15:3088-3103.
80. Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, Yoshikawa K, Akira S, Takeda J. 1999. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphognesis. EMBO J 18:4657-4668.
81. Schaefer LK, Ren Z, Fuller GN, Schaefer TS. 2002. Constitutive activation of Stat3alpha in brain tumors: Localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 21(13):2058-2065.
82. Schindler CW. 2002. Series Introduction: Jak-STAT signaling in human disease. J Clin Invest 109(9):1133-1137.
83. Schuringa JJ, Wojtachnio K, Hagens W, Vellenga E, Buys CH, Hofstra R, Kruijer W. 2001. MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 20(38):5350-5358.
84. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, Lee CK, Gerthner R, Kitamura T, Frantsve J, Anastasiadou E, Loh ML, Levy DE, Ihle JN, Gilliland DG. 2000. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6(3):693-704.
85. Scwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Peeters P, Van Rompaey L, Van Etten RA, Ilaria R, Jr, Marynen P, Gilliland DG. 1998. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/ JAK2 fusion genes. EMBO J 17(18):5321-5333.
86. Shuai K. 1999. The STAT family of proteins in cytokine signaling. Prog Biophys Mol Biol 71:405-422.
87. Shuai K. 2000. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 19:2638-2644.
88. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. 1996. Costitutive activation of Stat5 by the Bcr-Abl oncogene in chronic myelogenous leukemia. Oncogene 13:247-254.
89. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, Fernandez-Luna JL. 1999. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 274(32):22165-22169.
90. Simononic PD, Lee-Loy A, Barder DL, Tremblay ML, McGlade CJ. 2002. The T cell protein tyrosine phosphatase is a negative regulator of Janus family kinases 1 and 3. Curr Biol 12:446-453.
91. Sinibaldi D, Wharton W, Turkson J, Bowman T, Peters G, Pledger WJ, Jove R. 2000. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblast: Role of activated Stat3 signaling. Oncogene 19:5419-5427.
92. Smith PD, Crompton MR. 1998. Expression of v-src in mammary epithelial cells induces transcription via STAT3. Biochem J 331(Pt2):381-385.
93. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. 1999. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/-mice: A direct role for Stat5 in Bcl-X(L) induction. Cell 98:181-191.
94. Song JI, Grandis JR. 2000. Stat signaling in head and neck cancer. Oncogene 19:2489-2495.
95. Spiekerman K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. 2002. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for trasformation of hematopoietic precursor cells. Exp Hematol 30:262-271.
96. Stark GR, Kerr IM, Williams BRG, Silvermann RH, Schreiber RD. 1998. How cells respond to interferons. Ann Rev Biochem 67:227-264.
97. Starr R, Hilton DJ. 1999. Negative regulation of theJAK/STAT pathway. Bioessays 21:47-52.
98. Takeda K, Akira S. 2000. STAT family of transcription factors in cytokine-mediated biological responses (Mini review). Cytokine Growth Factor Rev 11:199-207.
99. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S. 1997. Targed distruption of the mouse Stat3 gene to early embryonic lethality. Proc Natl Acad Sci USA 94:2607-2611.
100. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN. 1998. Stat5a and Stat5b proteins have essential and non essential, or redundant, roles in cytokine responses. Cell 93:841-850.
101. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay M, David M, Shuai K. 2002. Identification of a nuclear Statl protein tyrosine phosphatase. Mol Cell Biol 22(16):5662-5668.
102. Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN. 1996. Requirement for Stat4 in IL-12 mediated responses of natural killer and T-cells. Nature 382:171-174.
103. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. 1998. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18:2545-2552.
104. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebt S, Hamilton AD, Jove R. 2001. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation, and cell transformation. J Biol Chem 276:45443-45455.
105. Udy JB, Tower RP, Snell RG, Wilkins RJ, Park S-K, Ram FA, Waxman DJ, Davey HW. 1997. Requirement of Stat5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 94:7239-7244.
106. Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H, Elliott WL. 2000. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts. Cancer Chemother Pharmacol 45(3):231-238.
107. Wang D, Mariage R, Stravopodis D, Carpino N, Marine JC, Teglund S, Feng J, Ihle JN. 2000. A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5. EMBO J 19:392-399.
108. Williams JG. 1999. Serpentine receptors and STAT activation: More than one way to twin a STAT. Trends Biochem Sci 9:333-334.
109. Williams JG. 2000. STAT signaling in cell proliferation and in development. Curr Opin Genet Dev 10:503-507.
110. Yamada S, Shiono S, Joo A, Yoshimura A. 2003. Control mechanism of JAK/STAT signal transduction pathway. FEBS Letters 534:190-196.
111. You M, Yu DH, Feng GS. 1999. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated JAK-STAT pathway. Mol Cell Biol 19:2416-2424.
112. Yu CL, Jin YJ, Burakoff SJ. 2000. Cytosolic tyrosin dephosphorylation of STAT5. JBC 275(1):599-604.
113. Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitzki A, Kraker A, Krolewski JJ, Medveczky P, Jove R. 2000. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem 275(32):24935-24944.